CDNA CareDx Forecast, Technical & Fundamental Analysis
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers... Show more
CDNA is expected to report earnings to fall 31.76% to 23 cents per share on July 30
Q2'26
Est.
$0.23
Q1'26
Beat
by $0.40
Q4'25
Beat
by $0.11
Q3'25
Beat
by $0.36
Q2'25
Beat
by $0.20
The last earnings report on April 28 showed earnings per share of 34 cents, beating the estimate of -5 cents. With 160.06K shares outstanding, the current market capitalization sits at 1.49B.
A.I. Advisor
published General Information
General Information
a molecular diagnostics company which develops, markets and delivers diagnostic surveillance solutions for organ transplant recipients
A.I.dvisor indicates that over the last year, CDNA has been loosely correlated with BLFS. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if CDNA jumps, then BLFS could also see price increases.
Aroon Indicator for CDNA shows an upward move is likely
CDNA's Aroon Indicator triggered a bullish signal on June 26, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 169 similar instances where the Aroon Indicator showed a similar pattern. In of the 169 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on May 27, 2026. You may want to consider a long position or call options on CDNA as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CDNA just turned positive on June 10, 2026. Looking at past instances where CDNA's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CDNA advanced for three days, in of 282 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CDNA broke above its upper Bollinger Band on June 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CDNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.127) is normal, around the industry mean (12.434). P/E Ratio (14.887) is within average values for comparable stocks, (145.945). CDNA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.488). CDNA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.008). P/S Ratio (3.201) is also within normal values, averaging (7.258).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
